KRAS and neoplasm: STK11/LKB1 tumours are associated with a lower expression of immune markers (e.g., PD-L1) if KEAP1 is co-mutated, correlating to resistance to PD-1 blockade in KRAS-mutated lung adenocarcinoma [22].